Muhammad Asad Sardar

Group Brand Manager

WHAT IS UNIVERSALLY ACCLAIMED?

UNICLIN-Introduction:

• Broad-spectrum

• Semi-synthetic Antibiotic

• Bactericidal Antibiotic

• Clindamycin is in a same class of

medications called Lincosamides.

• It works by slowing or stopping the

growth of bacteria.

MODE OF ACTION:

• Lincosamides prevent bacteria

replicating by interfering with the

synthesis of proteins.

• They bind to the 23s portion of the 50S

subunit of bacterial ribosomes and cause

premature dissociation from the

ribosome.

DO LINCOSAMIDES REACT WITH

HUMAN CELLS?

• Lincosamides do not interfere with

protein synthesis in human cells (or those

of other eukaryotes) because human

ribosomes are structurally different from

those of bacteria.

SIDE EFFECTS:

More common• Abdominal or stomach cramps and pain

• Abdominal tenderness

• Diarrhea (watery and severe), which may also be bloody

• Fever

Less common• Sore throat and fever

• Skin rash, redness, and itching

• Unusual bleeding

IN PREGNANCY:

• Clindamycin has been assigned to pregnancy category B by the FDA (Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.)

• Clindamycin has been used during pregnancy and labor and delivery without adverse effects in the fetus or neonate.

• Clindamycin is only recommended for use during pregnancy when benefit outweighs risk.

IN NURSING MOTHER:

• A Concentrations of 0.7 to 3.8 mcg/mL of Clindamycin have been reported into human milk.

• Adverse gastrointestinal effects have been reported in one nursing infant exposed to multiple drugs including Clindamycin.

• Due to the potential for adverse effects in neonates, a decision should be made to discontinue nursing or discontinue the drug.

Date Presentation title 13

• The penicillins have historically been used

as the first-line therapy in Odontogenic

Infections, but increasing rates of resistance

have lowered their usefulness.

• Clindamycin is an attractive first-line

therapy in the treatment of Odontogenic

infections.

Date Presentation title 15

Date Presentation title 16

Date Presentation title 17

Date Presentation title 18

FEATURES & BENEFITS:

• Excellent Penetration

• Lower MICs

• Safe & Tolerable

• Quality with Economy

• Simple & Convenient Dosage

PSEUDOMEMBRANOUS COLITIS

• Pseudomembranous colitis is infection of the large intestine (colon) with an overgrowth of Clostridium difficile bacteria***.

• The Clostridium difficile bacteria is normally seen in the intestine. However, it may overgrow when you take antibiotics. The bacteria release a powerful toxin that causes the lining of the colon to become inflamed and bleed***.

• The most common antibiotics associated with this condition are ampicillin, clindamycin, fluoroquinolones, and cephalosporin***.

Incidence:• Incidence rates for clindamycin-induced

pseudomembranous colitis are reported as 0.1% to 10%*

• The results suggest that the risks associated with the use of Clindamycin are acceptable if the drug is given for the approved specific indications.**

• Pseudomembranous colitis is rare in infants younger than 12 months old and uncommon in children***.

**Med J Aust. 1977 Feb 19;1(8):243-6

Take medication before half an hour of meal with full glass of

water.

References:

*Infectious Diseases in Children, January 2005

**Med J Aust. 1977 Feb 19;1(8):243-6

***Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431-455.

***Gerding DN, Johnson S. Clostridial infections. In: Goldman L, Schafer AI, eds. Cecil Medicine. 24th ed. Philadelphia, Pa: Saunders Elsevier; 2011:chap 304.

***Thielman NM, Wilson KH. Antibiotic-associated colitis. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, Pa: Elsevier Churchill Livingstone; 2009:chap 96.

Date Presentation title 24